$599
Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics

Amgen and MannKind Q2 ’25 Earnings; Sava Raises $19M for Biosensor Development; MetaVia Extends Ph1 Obesity Study 

A series of cardiometabolic-related news items has been observed from Amgen, MannKind, Sava Technologies, and MetaVia. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here
OR
Return to Home